Authors
Latest:
Using Digital Technology to Empower Patients and Restore TrustLooking at the road ahead to properly utilizing digital technology in clinical trials.
Latest:
Empowering the Workforce of the Future: The Trends and Training That Will Drive the Future of Drug DevelopmentA new global report finds that clinical research teams are making progress but still lack the skills and tools needed to keep pace with growing trial complexity and emerging technologies.
Latest:
The Impact of Decentralized and Hybrid Trials on Sponsor and CRO CollaborationsTufts CSDD study in collaboration with ten biopharmaceutical organizations and CROs examines sponsor/CRO relationships.
Latest:
COPD: Therapies on the CuspClinical trials in this area reflect new science, and corresponding challenges in their execution.
Latest:
Beyond the Black Box: Tailoring AI Regulation in HealthcareAs adoption increases, regulatory bodies are becoming more involved in the oversight of artificial intelligence.
Latest:
A Digital Twin on CAR-T Cytokine Release Syndrome (CRS) Patients with Standard of Care Measured by CRS Distribution by GradeUsing existing clinical trial data to proactively model patient safety and efficacy outcomes could aid in accelerating development for areas in need of new therapies.
Latest:
Evolving Tools and Perspectives for the Development of Cell and Gene TherapiesStakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Latest:
Applied AI and Advanced Automation in Clinical TrialsUse cases spotlight the growing potential of generative AI in the CRO space.
Latest:
Scaling eSource-Enabled Clinical Trials: Hospital PerspectivesThe challenges, opportunities, and strategic outlook for oncology research centers.
Latest:
Self-collection of Blood Specimens in Clinical TrialsOperational and patient burden considerations for self-collection of blood specimens in clinical trials
Latest:
Cancer Won’t Wait for COVID to End: Conducting Trials Amid the Coronavirus PandemicThousands of trials have been halted as a consequence of the coronavirus pandemic, slowing the pace of scientific progress dramatically.
Latest:
5 Reasons Physicians Should Integrate Clinical Trials Into Their PracticeUsing IROs can offer the opportunity for doctors to incorporate clinical research as a care option in their practices.
Latest:
Streamlining Clinical Trials: Mitigation and ManagementHow service providers are helping to accelerate drug development.
Latest:
At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ DeviceLaboratory services organization focuses on easing patient and site burden with improved collection device.
Latest:
What Do COVID-19 Vaccine Timelines Mean For Clinical Development?The pandemic spurred an urgency to innovate that improved clinical development in ways that should benefit the industry beyond COVID-19.
Latest:
Towards a Global Implementation of eConsent in Clinical TrialsAll stakeholders must play part in increasing implementation.
Latest:
America’s Vanishing Scientific Research Workforce is a Threat to Public HealthAs biotech innovation accelerates, the clinical research workforce is rapidly eroding—threatening the future of drug development. From workforce burnout to training program cuts and talent pipeline collapse, clinical trial professionals must confront this escalating crisis head-on to sustain progress and protect public health.
Latest:
Creating Strategic Relationships: The Changing Face of Contract Research Organizations and Sponsor PartnershipsBy taking on tasks such as clinical trial management, logistics, statistics, and data management, contract research organizations have helped expand the capabilities of their sponsor partners and accelerate drug development timelines.
Latest:
Helping Rescued Adjudication Committees Get Back on TrackDetermining if an EAC is at risk and key actions to mitigate trial impact.
Latest:
Where Innovation and Patients Meet to Improve Cancer CarePromising scientific advances are pacing oncology drug development.
Latest:
Clinical Trial Monitoring: Should Randomization Be Included?While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.
Latest:
Changing the Paradigm in AI ImplementationHow pharma companies can reduce the risk of failure with AI-based innovations.
Latest:
FDA’s New Diversity Plan Guidance, And What It Means for Sponsors Developing Cancer DrugsGuidance will compel sponsors to consider new enrollment strategies and to be more diverse.
Latest:
Community Pharmacies Can Help Bridge the Diversity GapThrough grassroots patient education, local pharmacies serve as a pivotal doorway to improving access to trials.
Latest:
FDA’s Project Optimus Guidance: Highlights and Tips for Success for Oncology Drug DevelopersJanuary 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.
